177 related articles for article (PubMed ID: 21466356)
1. Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology.
Dewar R; Fadare O; Gilmore H; Gown AM
Arch Pathol Lab Med; 2011 Apr; 135(4):422-9. PubMed ID: 21466356
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
Popnikolov NK; Cavone SM; Schultz PM; Garcia FU
Mod Pathol; 2005 Dec; 18(12):1535-41. PubMed ID: 16258511
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
4. D2-40: an additional marker for myoepithelial cells of breast and the precaution in interpreting tumor lymphovascular invasion.
Ren S; Abuel-Haija M; Khurana JS; Zhang X
Int J Clin Exp Pathol; 2011 Jan; 4(2):175-82. PubMed ID: 21326813
[TBL] [Abstract][Full Text] [Related]
5. The role of immunohistochemistry in the differential diagnosis of breast lesions.
Moriya T; Kozuka Y; Kanomata N; Tse GM; Tan PH
Pathology; 2009 Jan; 41(1):68-76. PubMed ID: 19089742
[TBL] [Abstract][Full Text] [Related]
6. The usefulness of p63 as a marker of breast myoepithelial cells.
Batistatou A; Stefanou D; Arkoumani E; Agnantis NJ
In Vivo; 2003; 17(6):573-6. PubMed ID: 14758723
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast.
Hilson JB; Schnitt SJ; Collins LC
Am J Surg Pathol; 2010 Jun; 34(6):896-900. PubMed ID: 20463570
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry for diagnosis and prognosis of breast cancer: a review.
Bonacho T; Rodrigues F; Liberal J
Biotech Histochem; 2020 Feb; 95(2):71-91. PubMed ID: 31502889
[TBL] [Abstract][Full Text] [Related]
9. Myoepithelial cells in lobular carcinoma in situ: distribution and immunophenotype.
Wang Y; Jindal S; Martel M; Wu Y; Schedin P; Troxell M
Hum Pathol; 2016 Sep; 55():126-34. PubMed ID: 27195907
[TBL] [Abstract][Full Text] [Related]
10. Use of immunohistochemistry in the diagnosis of problematic breast lesions.
Lee AH
J Clin Pathol; 2013 Jun; 66(6):471-7. PubMed ID: 23486609
[TBL] [Abstract][Full Text] [Related]
11. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.
Rabban JT; Chen YY
Hum Pathol; 2008 Feb; 39(2):175-83. PubMed ID: 18206495
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic alterations in myoepithelial cells of the breast in normal and pathologic conditions.
Pusztaszeri M
Am J Surg Pathol; 2010 Dec; 34(12):1886; author reply 1886-7. PubMed ID: 21107098
[No Abstract] [Full Text] [Related]
13. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications.
Hilson JB; Schnitt SJ; Collins LC
Am J Surg Pathol; 2009 Feb; 33(2):227-32. PubMed ID: 18936688
[TBL] [Abstract][Full Text] [Related]
14. Myoepithelial cell differentiation markers in ductal carcinoma in situ progression.
Russell TD; Jindal S; Agunbiade S; Gao D; Troxell M; Borges VF; Schedin P
Am J Pathol; 2015 Nov; 185(11):3076-89. PubMed ID: 26343330
[TBL] [Abstract][Full Text] [Related]
15. Diminished number or complete loss of myoepithelial cells associated with metaplastic and neoplastic apocrine lesions of the breast.
Tramm T; Kim JY; Tavassoli FA
Am J Surg Pathol; 2011 Feb; 35(2):202-11. PubMed ID: 21263240
[TBL] [Abstract][Full Text] [Related]
16. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers.
Leibl S; Gogg-Kammerer M; Sommersacher A; Denk H; Moinfar F
Am J Surg Pathol; 2005 Mar; 29(3):347-53. PubMed ID: 15725803
[TBL] [Abstract][Full Text] [Related]
17. CD10 (Neutral Endopeptidase) Expression in Myoepithelial Cells of Salivary Neoplasms.
Neves Cde O; Soares AB; Costa AF; de Araujo VC; Furuse C; Juliano PB; Altemani A
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):172-8. PubMed ID: 19752720
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining characteristics of low-grade adenosquamous carcinoma of the breast.
Kawaguchi K; Shin SJ
Am J Surg Pathol; 2012 Jul; 36(7):1009-20. PubMed ID: 22446941
[TBL] [Abstract][Full Text] [Related]
19. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.
Collins LC; Carlo VP; Hwang H; Barry TS; Gown AM; Schnitt SJ
Am J Surg Pathol; 2006 Aug; 30(8):1002-7. PubMed ID: 16861972
[TBL] [Abstract][Full Text] [Related]
20. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis.
Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M
Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
